Fréderique Brune

Fréderique Brune has extensive work experience in various roles and industries. Starting in 1991, they worked as an Assistant in Clinical Research at Laboratoires Jacques Logeais for one year. From 1992 to 2000, they served as an Officer in the Department of Fire Explosives and Environment at Institut de Recherche Criminelle de la Gendarmerie Nationale (IRCGN). In 2001, they joined Pierre-Fabre as an Analytical Manager and Project Leader for six years.

In 2007, they began working at LFB, where they held several positions. Fréderique started as a Project Leader and then became the Director of Monoclonal Antibodies Program and Project Leader for two years. From 2012 to 2016, they were the Director of Development Programs and Interim Head Pharmacist at LFB Biotechnologies. Fréderique'sresponsibilities included managing development projects for plasma-derived, recombinant, and transgenic proteins, leading to successful registrations in Europe. Additionally, they served as the Quality Director of Bioproduction at LFB from 2016 to 2017.

In 2017, Fréderique joined Innate Pharma as the Senior Director of Pharmaceutical Operations until 2019, when they took on the role of VP Development CMC and Supply Chain. Fréderique held this position until February 2022.

Most recently, in February 2022, they became the Chief Development Officer (CDO) at Mablink Bioscience.

Overall, Fréderique Brune has demonstrated a diverse set of skills and experience in various leadership and management roles within the pharmaceutical and biotechnology industries.

Fréderique Brune began their education in 1984 at Paris-Sud University (Paris XI), where they obtained a degree in Pharmacy in 1990. Fréderique then pursued further studies at University Paris VI from 1990 to 1991, earning a diploma in Experimental and clinical pharmacology.